ROLE OF MICROBIAL INFECTIONS AND BIOCHEMICAL DYSREGULATION IN LEUKEMOGENESIS, DISEASE PROGRESSION, AND DIAGNOSTIC BIOMARKERS: A REVIEW

Abstract

Uncontrolled hematopoietic cell growth and poor differentiation are hallmarks of leukemia, a diverse group of hematological cancers. A growing body of research indicates that leukemogenesis, illness progression, and clinical outcomes are significantly influenced by microbial infections and metabolic instability. Through processes like immunological dysregulation, genomic instability, chronic inflammation, and direct oncogenic transformation, a number of viruses, bacteria, and parasites have been linked to the development and spread of leukemia. Certain leukemia subtypes are closely linked to viral agents such as hepatitis viruses, Epstein-Barr virus (EBV), and human T-cell leukemia virus type-1 (HTLV-1), while bacterial and parasitic infections may indirectly contribute by causing oxidative stress and prolonged inflammatory reactions. Leukemic cell survival and proliferation are largely dependent on biochemical changes, including aberrant expression of enzymes and cellular metabolites, oxidative stress imbalance, altered cytokine signaling, and metabolic reprogramming. These metabolic alterations offer useful indicators for prognosis and diagnosis in addition to influencing the course of the disease and treatment resistance. Changes in immunological mediators, metabolic intermediates, inflammatory markers, and serum enzymes have demonstrated potential value in risk assessment, early diagnosis, and treatment response monitoring. The current understanding of the involvement of metabolic abnormalities and microbial infections in the development and course of leukemia is compiled in this study. 1Asma Tariq, 2Isra Saeed, 3Dr.Aamnah Sajid, 4Dr.Humaira Hashmat, 5Ayesha Kashif, 6Mudassar Mehmood, 7*Sidra Jabeen, 8Muhammad Umar 228 1. Introduction The unchecked growth and accumulation of aberrant hematopoietic cells in the bone marrow, peripheral blood, and occasionally extramedullary tissues is the hallmark of leukemia, a diverse collection of malignant illnesses. The main subtypes are acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, and chronic lymphocytic leukemia. It is typically categorized based on the affected cell lineage (myeloid or lymphoid) and disease progression rate (acute or chronic) (Short et al., 2021). Leukemia causes severe morbidity and mortality in all age categories, making it a major global health burden.Leukemia accounts for a significant fraction of cancer incidence and fatalities globally, with notable geographic and demographic variations caused by environmental, genetic, and socioeconomic factors, according to latest global cancer estimates (Sung et al., 2021). Leukemia's biological heterogeneity, recurrent relapse, and drug resistance make it difficult to treat despite advancements in molecular diagnostics and targeted medicines. This emphasizes the significance of understanding the disease's etiological and pathogenic pathways. Improving prevention, early detection, and treatment outcomes requires an understanding of the pathogenic and etiological elements underlying leukemia. It is currently understood that leukemogenesis is a multistep process that disrupts normal hematopoiesis through immunological dysregulation, genetic abnormalities, epigenetic changes, and environmental exposures (Greaves, 2022). Even though somatic genetic changes are essential to malignant transformation, they frequently need cooperating internal or external stimuli to start or spread illness. A growing body of research indicates that host biochemical disorders and pathogenic pathogens may function as such cofactors, causing altered immune surveillance, persistent inflammation, and genomic instability. Particularly in people with underlying genetic predisposition, these mechanisms can foster the emergence and growth of malignant clones. Both epidemiological and mechanistic evidence support the focus on microbial infections as probable causes of leukemia. Human T-cell leukemia virus type 1, which is causally linked to adult T-cell leukemia/lymphoma, is one example of an oncogenic virus that has been directly linked to certain hematological malignancies (Cook et al., 2021). Other viral infections, such as Epstein-Barr virus, cytomegalovirus, and hepatitis viruses, may affect leukemia risk, disease progression, or treatment response through indirect mechanisms like immune modulation and chronic inflammatory signaling, according to recent research, which goes beyond established associations (de Martel et al., 2020). In the bone marrow microenvironment, persistent infections may promote leukemic transformation or clonal development by causing prolonged cytokine release, elevated oxidative stress, and compromised immune control. Additionally, it emphasizes the use of new laboratory biomarkers derived from biochemical and viral pathways for diagnosis, prognosis, and individualized illness therapy. The development of more effective leukemia prevention techniques, focused treatments, and sophisticated diagnostic instruments may be aided by an understanding of these interconnected pathways.